Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | PAM | P19021 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20503257 | 0.98 | DGKA (0.46) | DGKACTSKCNR2LMNAPAM | |
| SCHEMBL30516551 | 0.98 | DGKA (0.46) | DGKACTSKCNR2LMNAPAM | |
| SCHEMBL8002118 | 0.98 | DGKA (0.46) | DGKACTSKCNR2LMNAPAM | |
| SCHEMBL31088250 | 0.98 | DGKA (0.46) | DGKACTSKCNR2LMNAPAM | |
| SCHEMBL1638343 | 0.95 | CTSK (0.43) | DGKACTSKCNR2CA12CA1 | |
| SCHEMBL7284817 | 0.88 | DGKA (0.47) | DGKAMAPTCA12CA1 | |
| SCHEMBL377844 | 0.87 | ALDH1A1 (0.41) | CTSKCA12CA1CA7CA14 | |
| SCHEMBL28651273 | 0.86 | HDAC4 (0.40) | CTSKCA12CA1CA7CA14 | |
| SCHEMBL9752887 | 0.85 | TDP1 (0.37) | CTSKCA12CA1CA7CA14 | |
| SCHEMBL7119549 | 0.84 | TDP1 (0.50) | CTSKCNR2CA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991525-A1 | CYCLOHEXYLAMINO, BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | Serenex, Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| WO-2007101156-A1 | CYCLOHEXYLAMINO, BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2007-09-07 | — | — | WO | claimed |
| EP-4707404-A2 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | Ventana Medical Systems, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3492919-B1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2026-01-21 | — | — | EP | disclosed |
| CN-114395050-B | Amatoxin-antibody conjugates | 海德堡医药有限责任公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119570022-A | Ring-opening polymerization method for initiating 2-oxazoline by trifluoromethyl sulfonate trimethyl silicone ester | 华东理工大学深圳研究院 | 2025-03-07 | — | — | CN | disclosed |
| US-12215118-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4366777-A2 | LINKERS, DRUG LINKERS AND CONJUGATES THEREOF AND METHODS OF USING THE SAME | PROFOUNDBIO US CO. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240018174-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | VENTANA MED SYST INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11780863-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-116731101-A | Derivatives of N-caproic acid-L-tyrosine-L-isoleucine- (6) -aminocaproamide for the treatment of various diseases | 雅斯娜 | 2023-09-12 | — | — | CN | disclosed |
| CN-102702300-B | Compound for preventing or treating autoimmune diabetes and preparation method and application thereof | WEST CHINA HOSPITAL SICHUAN UNIV | 2014-12-24 | — | — | CN | disclosed |
| EP-0927049-B1 | LABELLED ELASTASE INHIBITORS | AMERSHAM PLC (GB) | 2005-05-11 | — | — | EP | disclosed |
| US-6375926-B1 | HUMAN LEUCOCYTE ELASTASE (HLE) INHIBITOR LABELLED WITH A DETECTABLE MOIETY WHERE THE INHIBITOR IS SYNTHETIC AND THE DETECTABLE MOIETY IS CHOSEN FROM A RADIOACTIVE ISOTOPE, A PARAMAGNETIC ION, A RADIOPAQUE COMPOUND AND AN ULTRASOUND | AMERSHAM INTERNATIONAL PLC | 2002-04-23 | — | — | US | disclosed |
| EP-0624377-B1 | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6214345-B1 | ANTITUMOR AGENTS; DRUG CONJUGATES WHICH ARE SELECTIVELY ACTIVATIBLE AT THE SITE OF THE TUMOR | BRISTOL-MYERS SQUIBB CO. | 2001-04-10 | — | — | US | disclosed |
| EP-0927049-A2 | LABELLED ELASTASE INHIBITORS | AMERSHAM INTERNATIONAL plc (GB) | 1999-07-07 | — | — | EP | disclosed |
| CN-1195340-A | Inhibitors of farnesyl-protein transferase | MERCK & CO INC (US) | 1998-10-07 | — | — | CN | disclosed |
| WO-1998010800-A2 | LABELLED ELASTASE INHIBITORS | AMERSHAM INTERNATIONAL PLC (GB) | 1998-03-19 | — | — | WO | disclosed |
| EP-0624377-A2 | Lysosomal enzyme-cleavable antitumor drug conjugates | Bristol-Myers Squibb Company (US) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780863-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | DGKA 2956/4885CTSK 2583/4885CNR2 4779/4885 |
| US-12215118-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | DGKA 2956/4885CTSK 2583/4885CNR2 4779/4885 |
| US-20240018174-A1 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | NQO2, SQOR, MRM1 | DGKA 2956/4885CTSK 2583/4885CNR2 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.